Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 14, 2026
Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 30, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Journal: The New England journal of medicine
Published: March 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
Journal: The New England journal of medicine
Published: February 25, 2026
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.
Journal: Cancer research communications
Published: February 04, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 26, 2025
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 01, 2025
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Journal: Cancer research communications
Published: September 24, 2025
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.
Journal: Cancer research communications
Published: September 24, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
Journal: Nature medicine
Published: September 04, 2025
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.
Journal: Clinical and translational science
Published: September 04, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 08, 2025
Last Updated: 09/26/2026